Results 41 to 50 of about 2,979 (199)

Adjunctive Cariprazine in Major depressive disorder: a Systematic review and Meta-analysis (a Pre-Registration Protocol).

, 2022
A systematic review and meta-analysis of adjunctive cariprazine in major depressive ...
Chawisa Suradom, Sirijit Suttajit, Manit Srisurapanont   +2 more
core   +3 more sources

Relationship Between Plasma Concentrations and Clinical Effects of Cariprazine in Patients With Schizophrenia or Bipolar Mania

Clinical and Translational Science, 2020
Population pharmacokinetic/pharmacodynamic modeling (via NONMEM) was used to describe longitudinal exposure‐response relationships for total cariprazine (sum of cariprazine and its major active metabolites) in 2,558 patients with schizophrenia or bipolar
Antonia Periclou, Susan Willavize, David Jaworowicz, Julie Passarell, Timothy Carrothers, Parviz Ghahramani, Suresh Durgam, Willie Earley, Margit Kapás, Tatiana Khariton   +9 more
doaj   +1 more source

Preferential Effects of Cariprazine on Counteracting the Disruption of Social Interaction and Decrease in Extracellular Dopamine Levels Induced by the Dopamine D3 Receptor Agonist, PD-128907 in Rats: Implications for the Treatment of Negative and Depressive Symptoms of Psychiatric Disorders

Frontiers in Psychiatry, 2022
The negative and cognitive symptoms of schizophrenia and related disorders may be due to reduced dopaminergic tone in cortical brain areas. Alteration in the function of dopamine (DA) D3 receptors may play a role in this cortical hypofunctionality and ...
Jan Kehr, Jan Kehr, Fu-Hua Wang, Fumio Ichinose, Shimako Yoshitake, Shimako Yoshitake, Bence Farkas, Béla Kiss, Nika Adham   +8 more
doaj   +1 more source

Cariprazine in Three Special Different Areas: A Real-World Experience

Neuropsychiatric Disease and Treatment, 2021
Camilla Gesi,1 Silvia Paletta,2 Maria Carlotta Palazzo,1 Bernardo Dell’Osso,1,3 Claudio Mencacci,1 Giancarlo Cerveri2 1Department of Mental Health and Addiction, ASST FBF Sacco, Milan, Italy; 2Department of Mental Health and Addiction, ASST Lodi, Lodi ...
Gesi C, Paletta S, Palazzo M C, Dell'Osso B, Mencacci C, Cerveri G   +5 more
doaj  

Case Report: Functional and Symptomatic Improvement With Cariprazine in Various Psychiatric Patients: A Case Series

Frontiers in Psychiatry, 2022
Cariprazine is a third-generation antipsychotic medication approved for the treatment of schizophrenia and bipolar disorder, with unique pharmacodynamic and pharmacokinetic properties.
Tommaso Vannucchi, Costanza Taddeucci, Lorenzo Tatini   +2 more
doaj   +1 more source

Cariprazine as a useful treatment for patients with schizophrenia and antipsychotic-induced extrapyramidal symptoms: a case report and literature review

European Psychiatry, 2022
Introduction The discovery of second-generation antipsychotics represented an authentic breakthrough for the management of psychotic disorders. Nevertheless, they still don’t adequately manage some aspects of these disorders, such as negative symptoms ...
C. Llach, L. Ilzarbe, M. Sagué-Vilavella, N. Arbelo, R. Catalan, F. Gutierrez   +5 more
doaj   +1 more source

Treating schizophrenia with cariprazine: from clinical research to clinical practice. Real world experiences and recommendations from an International Panel

Annals of General Psychiatry, 2020
Background Management of schizophrenia is sub-optimal in many patients. Targeting negative symptoms, among the most debilitating aspects of schizophrenia, together with positive symptoms, can result in significant functional benefits and dramatically ...
Andrea Fagiolini, José Ángel Alcalá, Thomas Aubel, Wojciech Bienkiewicz, Mats Magnus Knut Bogren, Joaquim Gago, Giancarlo Cerveri, Michael Colla, Francisco Collazos Sanchez, Alessandro Cuomo, Frieling Helge, Eduardo Iacoponi, Per-Axel Karlsson, Pradeep Peddu, Mauro Pettorruso, Henrique Jorge Ramos Pereira, Johan Sahlsten Schölin, Ingo Bernd Vernaleken   +17 more
doaj   +1 more source

Tolerability of cariprazine in the early stage of schizophrenia: A pooled, post-hoc analysis of 4 phase ii/iii double-blind placebo-controlled trials

European Psychiatry, 2021
Introduction In the early stage of schizophrenia (first 5 years), the most important clinical target besides symptom control is relapse prevention as each relapse significantly decreases the possibility of preferable long-term outcomes.
Z.B. Dombi, K. Acsai, Á. Barabássy, B. Sebe, I. Laszlovszky, G. Vass, B. Szatmári, M. Patel, W. Earley, G. Németh   +9 more
doaj   +1 more source

Cariprazine Orodispersible Tablet: A New Formulation for Cariprazine

Pharmacopsychiatry
Abstract IntroductionCariprazine is an atypical dopamine receptor partial agonist antipsychotic available in the form of capsules. Although capsules are one of the most desirable routes of administration, there are certain situations (e.
Meszár, Viktória, Magyar, Gabriella, Pásztor, Gabriella Mészárosné, Szatmári, Balázs, Péter, Krisztina, Marton, Lívia, Dombi, Zsófia B., Barabássy, Ágota   +7 more
openaire   +2 more sources

Cariprazine in Three Acute Patients with Schizophrenia: A Real-World Experience.

, 2021
There are still some unmet needs in the treatment of schizophrenia like the persistence of negative symptoms. Cariprazine is a new-generation antipsychotic with partial agonism of the dopamine receptors, distinct from other antipsychotics by its 10 times
Hernández-Huerta, Daniel, Montes, Jose M, Montes, Paloma   +2 more
core   +1 more source